Citations

Mayo Clinic

Clear

44 citation(s) found for "Haak, A J".

RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation
Oh, Raymond , Haak, Andrew J. , Smith, Karry M. J. , Ligresti, Giovanni , Choi, Kyoung Moo , Xie, Tiao , Wang, Shaohua , Walters, P. , Freeman, Michelle, Manlove, L., Chu, Vivian, Roden, Anja C. , Schymeinsky, Jürgen , Prakash, Y. S. , Vassallo, Robert , Tschumperlin, Daniel J. , Oh, Raymond S , Walters, Paula R, Freeman, Michelle R, Manlove, Logan J, Chu, Vivian M, Tschumperlin, Daniel J , Prakash, Y S , Vassallo, Robert , Thompson, Michael A. , Feghali‐Bostwick, Carol A. , Pabelick, Christina M.

Journal of Cell Science | May 15, 2018 | Volume: 131 | Issue: 10 | Pages: No page available

10.1242/jcs.209932 | PMID 29678906 Get It

ABSTRACT Myofibroblasts play key roles in wound healing and pathological fibrosis. Here, we used an RNAi screen to characterize myofibroblast regulatory genes, using a high-content imaging approach to quantify α-smooth muscle actin stress fibers in cultured human fibroblasts. Screen hits were validated on physiological compliance hydrogels, and selected hits tested in primary fibroblasts from patients with idiopathic pulmonary fibrosis. Our RNAi screen led to the identification of STAT3 as an essential mediator of myofibroblast activation and function. Strikingly, we found that STAT3 phosphorylation, while responsive to exogenous ligands on both soft and stiff matrices, is innately active on a stiff matrix in a ligand/receptor-independent, but ROCK- and JAK2-dependent fashion. These results demonstrate how a cytokine-inducible signal can become persistently activated by pathological matrix stiffening. Consistent with a pivotal role for this pathway in driving persistent fibrosis, a STAT3 inhibitor attenuated murine pulmonary fibrosis when administered in a therapeutic fashion after bleomycin injury. Our results identify novel genes essential for the myofibroblast phenotype, and point to STAT3 as an important target in pulmonary fibrosis and other fibrotic diseases.
Aging and anatomical variations in lung tissue stiffness
Sicard, Delphine , Haak, Andrew J. , Choi, Kyoung Moo , Craig, Alexandria R., Fredenburgh, Laura E. , Tschumperlin, Daniel J.

American Journal of Physiology-Lung Cellular and Molecular Physiology | February 22, 2018 | Volume: 314 | Issue: 6 | Pages: L946-L955

10.1152/ajplung.00415.2017 | PMID 29469613 Get It

Lung function is inherently mechanical in nature and depends on the capacity to conduct air and blood to and from the gas exchange regions. Variations in the elastic properties of the human lung across anatomical compartments and with aging are likely important determinants of lung function but remain relatively poorly characterized. Here we applied atomic force microscopy microindentation to characterize human lung tissue from subjects ranging in age from 11 to 60 yr old. We observed striking anatomical variations in elastic modulus, with the airways (200- to 350-µm diameter) the stiffest and the parenchymal regions the most compliant. Vessels (diameter < 100 µm) represented an intermediate mechanical environment and displayed diameter-dependent trends in elastic modulus. Binning our samples into younger (11–30 yr old) and older (41–60 yr old) groups, we observed significant age-related increases in stiffness in parenchymal and vessel compartments, with the most pronounced changes in the vessels. To investigate cellular mechanisms that might contribute to vascular stiffening with aging, we studied primary human pulmonary artery smooth muscle cells from subjects ranging in age from 11 to 60 yr old. While we observed no change in the mechanical properties of the cells themselves, we did observe trends toward increases in traction forces and extracellular matrix deposition with aging. These results demonstrate age-related changes in tissue mechanical properties that likely contribute to impaired lung function with aging and underscore the potential to identify mechanisms that contribute to mechanical tissue remodeling through the study of human cells and tissues from across the aging spectrum.
P127 RNAi screening to identify genes essential for myofibroblast activation.
Oh, Raymond , Haak, Andrew J. , Tschumperlin, Daniel J.

QJM: An International Journal of Medicine | January 31, 2017 | Volume: 109 | Issue: suppl_1 | Pages: S65-S65

10.1093/qjmed/hcw120.028 Get It

The past, present, and future of telemedicine for Parkinson's disease
Achey, Meredith A. , Aldred, Jason , Aljehani, Noha, Bloem, Bastiaan R. , Biglan, Kevin , Chan, Piu, Cubo, Esther , Dorsey, E. Ray , Guttman, Mark, Hassan, Anhar , Khandhar, Suketu M., Spindler, Meredith , Haak, Pieter van den , Walker, Richard , Wilkinson, Jayne , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task, Goetz, Christopher G. , Mari, Zoltan K. , Tanner, Caroline M. , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task

Movement Disorders | May 17, 2014 | Volume: 29 | Issue: 7 | Pages: 871-883

10.1002/mds.25903 | PMID 24838316 Get It

ABSTRACT Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more‐extensive, less‐expensive participation in research. © 2014 International Parkinson and Movement Disorder Society